Why efficacy boundaries are needed
In a group sequential trial, the treatment effect is examined at several planned times rather than only once at the end. Repeatedly looking at the accumulating results and stopping whenever an ordinary single-analysis test is significant can change the chance of a false positive. A sequential efficacy rule therefore specifies, before the results are examined, both when the analyses occur and how strong the evidence must be at each one.
This tutorial develops the basic rule for a one-sided Z-statistic design. Its purpose is to identify the planned looks, calculate the statistic at each look, and determine whether the trial crosses an efficacy boundary for the first time. It does not specify how to calibrate a particular boundary shape; the critical values are treated as design inputs.
Planned looks and one-sided Z statistics
Information measures the precision available for estimating the treatment effect; it is not necessarily the number of participants enrolled. For example, with a continuous outcome and a known variance, information can be represented as the reciprocal of the variance of the effect estimate. In other settings, the relationship between sample size, events, and information depends on the design and analysis. The look schedule should be stated in terms of the planned information targets, with the corresponding operational timing defined in the protocol.
Let \(\theta\) denote the treatment effect, with positive values defined in advance as beneficial. At look \(k\), let \(\hat{\theta}_k\) be its estimate and \(SE_k\) its standard error. The one-sided hypotheses are \(H_0:\theta\leq 0\) and \(H_a:\theta>0\). The boundary between these hypotheses is \(\theta=0\).
For a canonical information-based model, the standard error is approximately \(1/\sqrt{I_k}\). If \(U(I_k)\) is the cumulative score at information \(I_k\), then \(Z_k=U(I_k)/\sqrt{I_k}\). Under the null boundary \(\theta=0\), the score has mean zero and variance \(I_k\), so \(Z_k\) is approximately standard normal at each look. Under an alternative effect \(\theta\), the model gives an approximate mean of \(\theta\sqrt{I_k}\).
The standard group sequential approximation also assumes that score increments from non-overlapping information intervals are independent and approximately normal. The resulting Z statistics at different looks are not independent. For \(i<j\), the canonical joint model gives:
The middle equality uses the independent-increment model: the shared portion of the two cumulative scores is the score through information \(I_i\), with variance \(I_i\). Since each Z statistic has variance approximately one under the null, the covariance here is also the correlation. This dependence is why a sequence of looks cannot be treated as a sequence of unrelated single-analysis tests.
Critical values and the first-crossing rule
For each planned look, the design specifies a critical value \(c_k\). In a one-sided efficacy design, the trial crosses the efficacy boundary at look \(k\) if \(Z_k\geq c_k\). A design may use different values at different looks. The values are part of the overall testing plan; they are not selected after seeing the observed statistics.
The “first” in first crossing matters. After a boundary is crossed, later statistics are not used to decide whether the trial should have stopped earlier. The rule is based on the ordered sequence of planned looks, not just on whether any statistic in a retrospectively assembled list happens to be large.
Worked Example: Crossing at the First Look
Suppose a hypothetical trial plans looks at information levels \(I_1=25\), \(I_2=60\), and \(I_3=100\). Its one-sided efficacy critical values, supplied in advance for this example, are \(c_1=3.10\), \(c_2=2.45\), and \(c_3=2.00\). At the first look, the estimated beneficial effect is \(0.62\) outcome units and its standard error is \(0.20\) outcome units.
The first information fraction is \(t_1=25/100=0.25\). The first-look statistic is:
Because \(Z_1=3.10\geq c_1=3.10\), the statistic reaches the efficacy boundary at look 1. The first-crossing rule stops the trial for efficacy at that look; results from later planned looks are not needed for this decision. This example illustrates how to apply supplied critical values, not how to choose or calibrate them.
Worked Example: Continuing After a Non-Crossing Look
Use the same hypothetical information levels and critical values. At look 1, suppose \(\hat{\theta}_1=0.52\) outcome units and \(SE_1=0.20\) outcome units. If the trial continues to look 2, suppose the estimate is \(0.35\) outcome units and the standard error is \(0.1291\) outcome units.
At look 1, \(Z_1=0.52/0.20=2.60\), which is below \(c_1=3.10\). There is no efficacy crossing at this look, so the rule permits the trial to continue to its next planned look.
At look 2, the information fraction is \(t_2=60/100=0.60\), and:
Since \(2.711\geq c_2=2.45\), the first crossing occurs at look 2. The trial stops for efficacy there. The statistic at look 1 did not cross its own boundary, even though it was positive; positivity alone is not the stopping criterion.
How to apply the rule reliably
Identify the current cumulative information target and its position in the pre-specified sequence. Use the information actually available under the design’s stated analysis plan.
Use the specified effect estimate and standard error to calculate \(Z_k=\hat{\theta}_k/SE_k\), keeping the beneficial direction consistent with the hypothesis.
Check whether \(Z_k\geq c_k\), using the critical value for this look rather than one borrowed from another look.
If the inequality holds, this is the first crossing and the efficacy rule stops the trial. If it does not hold, continue only as specified in the protocol to the next planned look.
Worked Example: No Efficacy Crossing at the Planned Looks
A third hypothetical trial uses the same information levels and boundaries. Its estimated effects and standard errors yield \(Z_1=2.50\), \(Z_2=2.40\), and \(Z_3=1.95\). For illustration, the corresponding effect estimates are \(0.500\), \(0.3098\), and \(0.195\) outcome units, with standard errors \(0.200\), \(0.1291\), and \(0.100\) outcome units.
The calculations are \(0.500/0.200=2.50\), \(0.3098/0.1291\approx2.40\), and \(0.195/0.100=1.95\). Compare in order: \(2.50<3.10\) at look 1; \(2.40<2.45\) at look 2; and \(1.95<2.00\) at look 3. None reaches its look-specific boundary.
Thus there is no efficacy crossing in the planned sequence. The result is not proof that the treatment has no effect. It means only that the observed statistics did not meet the specified efficacy stopping criterion. Any further interpretation or action must follow the trial’s pre-specified plan.
Assumptions, diagnostics, and limitations
The rule is meaningful only when its design assumptions and implementation are credible. At minimum, the planned information levels, analysis times, effect direction, statistic, and critical values must be specified coherently. The Z approximation should be adequate for the endpoint and estimator at the looks being used. The standard error must reflect the intended analysis, including relevant features such as clustering, missing outcomes, or estimated variance when they affect precision. The canonical correlation model is an approximation, not a guarantee for every design.
Useful checks include comparing actual information at each analysis with the planned target; confirming that the effect estimate, standard error, and critical value all correspond to the same look; checking that higher values of \(Z_k\) really favor the intended beneficial direction; and verifying that analyses were not added, omitted, or shifted without an approved design-specific procedure. If the trial’s data structure or analysis differs materially from the assumptions used to set the rule, the nominal boundary comparison may no longer have its intended operating characteristics.
A boundary value is a threshold for a particular look, not a standalone statement about the entire sequence. In particular, interpreting each \(c_k\) as if it were an ordinary single-analysis cutoff does not account for the planned repeated opportunities to cross. The joint error-rate implications of multiple looks require design-level calibration; the boundary values must be considered as a sequence. The next step in the course’s treatment of classical boundaries is to examine that familywise error issue.
| Approach | Decision structure | Main distinction |
|---|---|---|
| Fixed-sample test | One analysis at a pre-specified final information level | No interim efficacy stopping decisions are made under the basic plan. |
| Repeated unadjusted single-analysis tests | Compare each interim statistic with a single-analysis cutoff | Does not, by itself, account for the sequence of opportunities to cross. |
| Planned sequential efficacy boundaries | Compare each statistic with its own pre-specified \(c_k\) and stop at the first crossing | Uses the full planned look structure; the sequence requires appropriate design-level calibration. |
A further limitation is that an efficacy boundary answers a narrow question: whether the statistic has crossed the pre-specified threshold in the beneficial direction. It does not by itself establish clinical importance, resolve safety concerns, or authorize an unplanned analysis. Nor does failure to cross an efficacy boundary imply that the treatment is ineffective. Those conclusions require additional evidence and the trial’s full decision framework.
Common mistake: treating looks as independent tests
A related error is to stop at the first positive statistic, regardless of its size. The efficacy rule requires \(Z_k\geq c_k\), not merely \(Z_k>0\). Another is to reverse the sign convention mid-analysis: if negative effects favor the intervention under the original definition, the statistic and one-sided alternative must be aligned before applying a positive-direction boundary.
Check Your Understanding
Answer each question using the first-crossing rule. Solutions follow.
- A design has boundaries \(c_1=3.0\), \(c_2=2.5\), and \(c_3=2.0\). Its statistics are \(Z_1=2.8\), \(Z_2=2.6\), and \(Z_3=2.4\). At which look, if any, does the trial stop for efficacy?
- At a planned look, the estimated beneficial effect is \(0.30\) outcome units and its standard error is \(0.15\) outcome units. Calculate \(Z\). If the boundary is \(2.10\), is there an efficacy crossing?
- Why can successive cumulative Z statistics not generally be treated as independent tests?
- If no statistic reaches its boundary, what does that establish, and what does it not establish?
Solutions. (1) At look 1, \(2.8<3.0\), so there is no crossing. At look 2, \(2.6\geq2.5\), so the first crossing is at look 2 and the trial stops there; the look-3 value is not used for this stopping decision. (2) \(Z=0.30/0.15=2.00\). Since \(2.00<2.10\), there is no crossing at this look. (3) The cumulative analyses share earlier observations or score increments; under the canonical model, for \(i<j\) their correlation is \(\sqrt{I_i/I_j}\), not zero. (4) It establishes that the planned efficacy boundary was not crossed at any planned look. It does not establish that the treatment has no effect or that there is no clinically meaningful benefit.